What's breaking now, across thousands of outlets.
The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
Medical devices are emerging as the new kid on the block in India’s healthcare investment landscape, attracting private equity (PE) interest on the back of a fragmented market, rising demand and the…
Thomas Kahlert has been off HIV treatment since 2018 after a stem-cell transplant from a donor who was not HIV-resistant. Why it matters, and why it isn’t a cure for most people with HIV.
Imagine a teenager in a vulnerable mental health crisis being admitted to a ward full of adults. Thankfully, regional officials […]
Estuary Biotherapeutics raised the curtain on Friday with $103 million to support the advancement of two preclinical gene therapy candidates for the most common type of inherited kidney disease.
The first two confirmed Ebola cases in Kenya have raised urgent questions about the country's public health preparedness and border controls. But the health ministry says there is no need for panic.
The first two confirmed Ebola cases in Kenya have raised urgent questions about the country's public health preparedness and border controls. But the health ministry says there is no need for panic.
